[ad_1]
Regulatory News:
THIS PRESS RELEASE SHOULD NOT BE PUBLISHED, DISTRIBUTED OR DISTRIBUTED,
TOTALLY OR PARTIALLY, DIRECTLY OR INDIRECTLY, TO
USA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA, OR
IN ANY OTHER JURISDICTION PROHIBITING SUCH PRACTICES
ASIT biotech (Paris: ASIT) (BSE: ASIT) (Euronext: ASIT – BE0974289218)
Belgian biopharmaceutical company specializing in the immunotherapy of
allergies, today announces a private placement ("the Offer") under
form of senior unsecured convertible bonds (the "OCs")
").
The accelerated construction process of a book of orders was initiated
this day, after the close of the markets. The results of the Offer will be
announced as soon as possible after the closing of the order book in a
Press release.
Trading in the securities of the Company on Euronext Brussels and
Euronext Paris will be suspended during the construction period of the
book of orders and should resume after the publication of the results
of the Offer.
***
About ASIT biotech
ASIT biotech is a Belgian biopharmaceutical company at the
clinical development specializing in the development and
future commercialization of a new generation of products
immunotherapy for allergies. Thanks to ASIT + ™, its technology
innovative, ASIT biotech is currently the only developer
allergenic immunotherapies using natural peptides
carefully selected and calibrated after being extracted
of highly purified natural allergens. The result of this
innovation is a short-term treatment, which should improve
acceptance and adherence to treatment by patients and their
efficiency in real life. The portfolio of ASIT Biotech comprises
three innovative product candidates, targeting respiratory allergies
with the highest prevalence (grbad pollen allergies
with gp-ASIT + ™ and mites with hdm-ASIT + ™) and allergies
(peanut allergy with pnt-ASIT + ™). These products
could significantly expand the current market
immunotherapy. Finally, the Company believes that its platform
innovative ASIT + ™ is flexible and applicable to other types of allergies.
ASIT biotech has 26 employees and employees. Its registered office is
in Brussels and its laboratories in Liège, Belgium.
More information on www.asitbiotech.com.
Forward-Looking Statements
All statements in this announcement that are not related to
events or historical data are statements
Prospective. In some cases, these forward-looking statements may
be identified by the use of words such as "believes", "esteem",
"Anticipates", "waits", "considers", "may", "will",
"Projects", "continues", "in progress", "potential", "omen",
"Target", "target", "search", or "should" or, in each case,
by their negative equivalent or comparable terminology, or when
discusses strategy, plans,
objectives, ambitions, goals, future events or intentions. The
forward-looking statements include statements about
intentions, beliefs and current expectations of the Company. By
their nature, forward-looking statements involve known risks
and unknown and uncertainty because they relate to events and
depend on circumstances that may or may not occur
in the future. Forward-looking statements are not the
guarantee of future performance. Taking into account these risks and
uncertainties, you should not rely on statements
provisions to predict actual results. all
forward-looking statement is made exclusively on the date of this
ad. The Company has no intention or commitment to
publish updates or revise forward-looking statements
contained in this press release as a result of new information,
recent or other events, except where required by law or
the rules.
Legal Warning
This press release does not constitute a prospectus or within the meaning of the
Directive 2003/71 / EC, as transposed into the national law of
each Member State of the European Economic Area, and its
amendments, including Directive 2010/73 / EU in so far as it
transposed into the national law of the Member State concerned
the European Economic Area (together the "Prospectus Directive") and
within the meaning of Regulation (EU) 2017/1129 on the prospectus to be published
in the event of an offer to the public of securities or for admission
securities at negotiation and repealing the Directive
2003/71 / EC (the "Prospectus Regulation").
In no case shall this press release constitute, nor disclose
constitute a public offer, a public offer for sale or
underwriting, a public solicitation of an offer to purchase or
subscription of securities in any jurisdiction. Or
ASIT Biotech SA, nor the single book content that the Company has appointed (the
"Single Bookrunner"), nor any of their respective affiliates have
taken steps to authorize a public offer of securities
securities mentioned in this press release, or the possession or
distribution of this press release in any jurisdiction where
such an approach would have been necessary.
No action has been or will be taken to propose to the
shares of ASIT Biotech SA in the context of an offer
would require the filing of a prospectus in a Member State of the European Space
European Economic Area in whose internal law the Prospectus Directive
has been transposed. Therefore, the shares of ASIT Biotech SA
may be offered or sold in a Member State concerned
only in a derogatory framework provided for by the Prospectus Directive.
No communication or information relating to the Offer shall be
be distributed to the public in territories where a registration
or an authorization is required for this purpose. No steps were nor
will be undertaken in a jurisdiction where such an approach would be
necessary. The Offer may be subject to legal prohibitions or
specific regulations in certain jurisdictions. ASIT Biotech SA
and the single bookrunner decline all responsibility in the event that
anyone who violates these prohibitions. It belongs in all
the reader of this release to inquire about the existence of
such prohibitions and to comply with them.
This news release is not to be released, published, distributed,
all or part, directly or indirectly, or in the United States (including
including its territories and dependencies, any state of the United States and the
District of Columbia), Australia, Canada, Japan, South Africa
South, or in any other jurisdiction where its publication or distribution
would break the law. This press release is purely for the purpose of
informative and can not constitute an offer for sale or issue,
the solicitation of an offer to buy or acquire shares of
ASIT Biotech SA in the United States, Australia, Canada, Japan,
South Africa, nor in a jurisdiction where such an offer or
solicitation would be illegal or require the filing of any
prospectuses or other documentation related to an offer, or in which a
registration, an exemption from registration or an approval
would be required before, pursuant to the securities laws
securities of such jurisdiction. Any breach of these obligations
would be likely to constitute a violation of the securities laws
securities of these territories. The titles that are for sale in the
part of the Offer did not and will not be the subject of a
registration under the US Securities Act
1933 (US Securities Act), as amended (the "US Securities Act").
Securities') and may not be offered, sold or badigned
directly or indirectly, in the United States, except
derogatory or in the context of a transaction not subject to the
registration under the US Securities Act
or the securities laws of any state or any other
other jurisdiction of the United States. The titles for sale mentioned in
this press release are not the subject of any public offer to
United States or elsewhere .
See the source version on businesswire.com: https://www.businesswire.com/news/home/20180710005864/en/
Source link
